Susquehanna International Group
EWTX icon

Susquehanna International Group’s Edgewise Therapeutics EWTX Stock Holding History

Susquehanna International Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$840K Sell
26,674
-43,522
-62% -$1.26M ﹤0.01% 8350
2025
Q4 		$1.74M Buy
70,196
+24,561
+54% +$493K ﹤0.01% 5933
2025
Q3 		$740K Sell
45,635
-69,635
-60% -$988K ﹤0.01% 8069
2025
Q2 		$1.51M Sell
115,270
-61,396
-35% -$885K ﹤0.01% 6424
2025
Q1 		$3.89M Buy
176,666
+144,953
+457% +$3.8M ﹤0.01% 4129
2024
Q4 		$847K Sell
31,713
-168,787
-84% -$5.37M ﹤0.01% 7382
2024
Q3 		$5.35M Buy
200,500
+183,724
+1,095% +$3.65M ﹤0.01% 3485
2024
Q2 		$302K Sell
16,776
-10,094
-38% -$176K ﹤0.01% 9434
2024
Q1 		$490K Sell
26,870
-27,566
-51% -$438K ﹤0.01% 8562
2023
Q4 		$596K Buy
+54,436
New +$382K ﹤0.01% 8233
2023
Q3 		– Sell
-11,735
Closed -$90.9K – 12262
2023
Q2 		$90.9K Sell
11,735
-5,150
-31% -$43.4K ﹤0.01% 11019
2023
Q1 		$113K Buy
+16,885
New +$157K ﹤0.01% 11193

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Susquehanna International Group's EWTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Edgewise Therapeutics (EWTX) stake by 62% in Q1 2026, selling an estimated $1.26M and leaving 26,674 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #8350.

Susquehanna International Group first reported a position in EWTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $5.35M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Susquehanna International Group held 26,674 shares of Edgewise Therapeutics worth $840K as of Q1 2026.
  • Susquehanna International Group sold 43,522 Edgewise Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Edgewise Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8350 holding.
  • Susquehanna International Group first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Susquehanna International Group's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.